




SUPPLEMENTARY MATERIAL TO  
**Development and validation of a solid phase extraction-HPLC  
method for the determination of carbamazepine and its  
metabolites, carbamazepine epoxide and carbamazepine  
trans-diol, in plasma**

PREDRAG DŽODIĆ<sup>1\*</sup>, LJILJANA ŽIVANOVIĆ<sup>2</sup>, ANA PROTIĆ<sup>2</sup>, IVANA IVANOVIC<sup>3</sup>,  
RADMILA VELIČKOVIĆ-RADOVANOVIĆ<sup>1</sup>, MIRJANA SPASIĆ<sup>1</sup>, STEVO LUKIĆ<sup>1</sup>  
and SLAVOLJUB ŽIVANOVIĆ<sup>1</sup>

<sup>1</sup>University of Niš, Faculty of Medicine, Bulevar dr Zorana Đindjića 81, 18000 Niš, Serbia,

<sup>2</sup>University of Belgrade, Faculty of Pharmacy, Department of Drug Analysis, Vojvode Stepe  
450, 11221 Belgrade, Serbia and <sup>3</sup>Avantor Performance Materials, Teugseweg 20,  
7400 AA Deventer, The Netherlands

J. Serb. Chem. Soc. 77 (10) (2012) 1423–1436



\*Corresponding author. E-mail: pdzodic@gmail.com




Fig. S-1. Representative chromatograms of blank plasma (a), blank plasma spiked with  $10 \mu\text{g mL}^{-1}$  of internal standard (b), blank plasma spiked with  $0.6 \mu\text{g mL}^{-1}$  of CBZ, CBZ-E, CBZ-DIOH and  $10 \mu\text{g mL}^{-1}$  of internal standard (c) and plasma sample of an epileptic patient (concentrations of CBZ, CBZ-E and CBZ-DIOH were  $7.12$ ,  $1.44$  and  $1.40 \mu\text{g mL}^{-1}$ , respectively) at  $9.0$  h after receiving an oral dose of  $200$  mg CBZ (d).